8-K: Beyond Air Prices $16 Million Registered Direct Offering of Common Stock and Warrants

Beyond Air, Inc. has announced a $16 million registered direct offering of common stock and warrants to institutional and accredited investors.

Summary

• Beyond Air, Inc. has entered into a securities purchase agreement for a registered direct offering.
• The offering includes 9,638,556 shares of common stock and warrants to purchase an additional 9,638,556 shares.
• The combined purchase price is $1.66 per share and accompanying warrant.
• The warrants are immediately exercisable at $2.25 per share and expire three years from issuance.
• The company may call the warrants if it reports at least $4.5 million in net sales for the quarter ending March 31, 2025, requiring exercise within 10 business days.
• The offering is expected to close around March 22, 2024, subject to customary conditions.
• Gross proceeds are estimated at $16 million before deducting fees and expenses.
• Net proceeds will be used for commercial sales development, research, working capital, and general corporate purposes.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is raising necessary capital, but the offering includes warrants that could dilute existing shareholders. The call provision on the warrants is a positive incentive, but the company must meet a sales target to trigger it.

Positives

• The offering provides Beyond Air with $16 million in gross proceeds to fund its operations.
• The funds will support commercial sales development, research, and working capital.
• The warrants have a call provision that could incentivize early exercise if the company meets a sales target.
• The offering is being conducted at-the-market under Nasdaq rules.

Negatives

• The offering includes warrants that could dilute existing shareholders if exercised.
• The company will incur placement agent fees and other offering expenses, reducing net proceeds.
• The call provision on the warrants could result in the company having to issue shares at a lower price than the current market price.

Risks

• The company may not achieve the $4.5 million net sales target to trigger the warrant call provision.
• The offering could dilute existing shareholders if the warrants are exercised.
• The company's use of proceeds may not yield the desired results.
• The company is subject to risks related to the ability to raise additional capital, clinical trials, regulatory approvals, competition, and intellectual property.

Future Outlook

The company intends to use the net proceeds from the offering to fund commercial sales development, research, working capital, and other general corporate purposes. The company is also advancing its LungFit systems in clinical trials and has partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders.

Industry Context

This offering is a common method for biotech companies to raise capital to fund research and development, as well as commercialization efforts. The use of warrants is a typical incentive for investors in such offerings.

Comparison to Industry Standards

• The structure of this offering, with a combination of common stock and warrants, is typical for small-cap biotech companies seeking capital.
• The warrant exercise price of $2.25 represents a premium over the offering price of $1.66, which is a common practice to incentivize investors.
• The call provision on the warrants is a less common feature, but it is designed to encourage early exercise if the company meets a specific sales target.
• Comparable companies that have recently conducted similar offerings include [list comparable companies if available], which have seen similar market reactions to such announcements.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• The company will have additional capital to fund its operations.
• The company's research and development efforts may benefit from the additional funding.
• The company's commercialization efforts may benefit from the additional funding.

Next Steps

• The company will close the offering on or about March 22, 2024.
• The company will use the net proceeds for commercial sales development, research, working capital, and other general corporate purposes.
• The company will continue to advance its LungFit systems in clinical trials.
• The company will continue to advance its pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders.

Key Dates

Keywords

registered direct offering, common stock, warrants, securities purchase agreement, at-the-market, placement agents, capital raise, dilution, LungFit, nitric oxide